Chemistry:Namodenoson
From HandWiki
Short description: Chemical compound
Clinical data | |
---|---|
Other names | Chloro-IB-MECA; 2-Cl-IB-MECA |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C18H18ClIN6O4 |
Molar mass | 544.73 g·mol−1 |
3D model (JSmol) | |
| |
|
Namodenoson is a small molecule A3 adenosine receptor (A3AR) agonist. It is developed by Can-Fite for non-alcoholic fatty liver disease,[1] liver cancer,[2] and pancreatic cancer.[3]
References
- ↑ Safadi, Rifaat; Braun, Marius; Francis, Adi; Milgrom, Yael; Massarwa, Muhammad; Hakimian, David; Hazou, Wadi; Issachar, Assaf et al. (December 2021). "Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis". Alimentary Pharmacology & Therapeutics 54 (11–12): 1405–1415. doi:10.1111/apt.16664. ISSN 1365-2036. PMID 34671996.
- ↑ Stemmer, Salomon M.; Manojlovic, Nebojsa S.; Marinca, Mihai Vasile; Petrov, Petar; Cherciu, Nelly; Ganea, Doina; Ciuleanu, Tudor Eliade; Pusca, Ioana Adriana et al. (7 January 2021). "Namodenoson in Advanced Hepatocellular Carcinoma and Child–Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial". Cancers 13 (2): 187. doi:10.3390/cancers13020187. ISSN 2072-6694. PMID 33430312.
- ↑ Fishman, Pnina; Bareket-Samish, Avital; Itzhak, Inbal (1 June 2023). "Effects of namodenoson on pancreatic carcinoma: Preclinical evidence.". Journal of Clinical Oncology 41 (16_suppl): e15134. doi:10.1200/JCO.2023.41.16_suppl.e15134.
Original source: https://en.wikipedia.org/wiki/Namodenoson.
Read more |